Ocular Therapeutix, Inc..
OCUL.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. The company's primary focus is on utilizing its proprietary bioresorbable hydrogel platform technology to develop sustained-release drug delivery systems...Show More
Better Health for All
40
Ocular Therapeutix, Inc. is entirely focused on the development of innovative therapies for eye diseases, indicating that 95-97% of its intended product portfolio is devoted to delivering exceptional health benefits.
1
The company's core business is research and development, with its entire pipeline dedicated to developing drug candidates and hydrogel delivery technology for retinal diseases, demonstrating that >25% of its R&D budget is allocated to health improvement.
2
The company holds a patent for an ocular implant, but there is no information regarding its approach to patent flexibility in relation to global health needs.
3
Fair Money & Economic Opportunity
0
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on eye diseases. The provided articles do not contain any specific, concrete data points or information relevant to the company's performance on the financial services-related KPIs for the 'Fair Money & Economic Opportunity' value.
1
As the company does not offer lending, deposit, or other financial services to consumers, all KPIs are scored as 0, indicating they are not applicable to its core business model as per the rubric.
Fair Pay & Worker Respect
20
In 2024, the CEO-to-median employee pay ratio was 33:1, with the CEO receiving $10,957,451 and the median employee earning $330,094.
1
The company covers 100% of medical, dental, and vision insurance premiums for employees and their dependents.
2
However, a consulting agreement with Dr. Thomas Ciulla, effective February 17, 2023, explicitly excludes him and his employees from company benefits, defining the relationship as an independent contractor.
3
The company laid off 25% of its staff (approximately 225 employees) in 2024, and an additional 13% (37 positions) of its full-time workforce were eliminated.
4
As of December 31, 2024, the company had approximately 4,396 regular full- and part-time employees and 1,196 contingent, subcontracted, and outsourced partners.
5
Employee ratings on Glassdoor show 76% would recommend working at the company to a friend, and 76% have a positive business outlook.
6
The overall employee rating is 3.8 out of 5 stars, with compensation and benefits rated 3.6 out of 5 stars.
7
Fair Trade & Ethical Sourcing
0
No specific, quantifiable evidence was found across the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. Information regarding fair-trade certified spend, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for ethical violations, ethical clause coverage in supplier contracts, share of high-risk materials, or supplier diversity spend is not present.
1
Honest & Fair Business
-40
The company has a comprehensive whistleblower policy, communicated to all staff, allowing for anonymous reporting 24/7 via multiple channels including a hotline and website, and explicitly prohibits retaliation, even for reporting to external authorities.
1
All employees, officers, and directors must certify they have read and understood the Code of Business Conduct and Ethics.
2
The company adopted a compensation recovery policy, effective October 2, 2023, in accordance with Nasdaq Listing Rule 5608, which requires recovery of incentive-based compensation in the event of an accounting restatement due to material non-compliance with financial reporting requirements.
3
The company's board of directors has adopted written policies for reviewing related person transactions where the amount exceeds the lesser of $120,000 or one percent of average total assets, and a majority of board members must be independent directors as per NASDAQ rules.
4
The company has a Code of Business Conduct and Ethics, revised in June 2025, that prohibits unlawful exchange of value, including bribes and kickbacks, and requires notification to the Chief Compliance Officer if contacted by a government entity regarding such matters.
5
The company utilizes a third-party identity verification service to match data points when processing requests and uses ProPharma Group for adverse event and product complaint reporting.
6
Kind to Animals
0
The provided articles do not contain specific data or metrics regarding Ocular Therapeutix, Inc.'s performance on animal welfare. , which summarizes the company's compliance program, explicitly states that no specific data on Kind to Animals or animal welfare metrics is provided.
1
discusses the FDA's general roadmap to reduce animal testing and legislative changes, but this information is not specific to Ocular Therapeutix, Inc.'s practices, policies, or animal testing volumes.
2
The content for was not provided.
3
No War, No Weapons
0
The provided articles do not contain any specific, concrete evidence regarding Ocular Therapeutix, Inc.'s involvement in arms manufacturing, military contracts, conflict facilitation, or any related initiatives such as peacebuilding investments, dual-use technology, or sales to embargoed regimes.
1
Both and explicitly state that no data relevant to these topics is mentioned.
2
Therefore, no KPIs under the 'No War, No Weapons' value can be scored based on the available information.
Planet-Friendly Business
0
No specific, quantifiable data was found in the provided articles to assess Ocular Therapeutix (OCUL.US) against the defined Planet-Friendly Business KPIs. While one article mentioned reduced Scope 3 emissions from reduced water purchases, no specific figures for emissions or water use were provided to allow for scoring.
1
Similarly, statements about 'no regulatory actions, violations, fines, or compliance issues are mentioned' do not constitute evidence of zero violations, but rather an absence of reported data, thus precluding a score for environmental compliance.
2
Respect for Cultures & Communities
0
No evidence available to assess Ocular Therapeutix, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Ocular Therapeutix, Inc. has a compliance program and makes an annual declaration of compliance with California Health and Safety Code §§ 119400-119402.
1
No regulatory actions, violations, fines, or compliance issues have been mentioned.
2
The company's privacy notice details user rights, including access, rectification, erasure, restriction, and portability.
3
The company uses NIST Cybersecurity Framework Special Publication 800-53 and NIST 800-61 as a guide for its cybersecurity program.
4
Zero Waste & Sustainable Products
-30
Ocular Therapeutix integrates circular design principles by utilizing its proprietary bioresorbable hydrogel platform technology, Elutyx, which eliminates the need for permanent implants in a variety of ophthalmic conditions.
1
The company has implemented 6 waste reduction initiatives, including actively recycling paper, packaging, coffee pods, and batteries, aiming for full composting, installing a reverse osmosis deionization (RODI) water system to reduce purified water purchases, treating wastewater to be pH neutral before discharge, working to shorten supply chains, and reducing the need for cold chain shipping.
2
For hazardous waste, the company treats wastewater to be pH neutral before discharge, indicating active reduction and proper handling.
3
No waste disposal violations or regulatory actions were mentioned.
4